Literature DB >> 21338273

Current status and prospects of gene therapy for the inner ear.

Hong Sun1, Aji Huang, Shousong Cao.   

Abstract

Inner ear diseases are common and often result in hearing disability. Sensorineural hearing loss is the main cause of hearing disability. So far, no effective treatment is available although some patients may benefit from a hearing aid equipped with a hearing amplifier or from cochlear implantation. Inner ear gene therapy has become an emerging field of study for the treatment of hearing disability. Numerous new discoveries and tremendous advances have been made in inner ear gene therapy including gene vectors, routes of administration, and therapeutic genes and targets. Gene therapy may become a treatment option for inner ear diseases in the near future. In this review, we summarize the current state of inner ear gene therapy including gene vectors, delivery routes, and therapeutic genes and targets by examining and analyzing publications on inner ear gene therapy from the literature and patent documents, and identify promising patents, novel techniques, and vital research projects. We also discuss the progress and prospects of inner ear gene therapy, the advances and shortcomings, with possible solutions in this field of research.

Entities:  

Mesh:

Year:  2011        PMID: 21338273      PMCID: PMC3225036          DOI: 10.1089/hum.2010.246

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  67 in total

1.  Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer.

Authors:  Hinrich Staecker; Mark Praetorius; Kim Baker; Douglas E Brough
Journal:  Otol Neurotol       Date:  2007-02       Impact factor: 2.311

2.  [Protective effect of NT-3 gene mediated by hydroxyapatite nanoparticle on the cochlea of guinea pigs injured by excitotoxicity].

Authors:  Ming Jiang; Yong-Quan Zhang; Guang-Xiang He; Hong Sun
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2007-08

3.  NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells.

Authors:  H Staecker; R Kopke; B Malgrange; P Lefebvre; T R Van de Water
Journal:  Neuroreport       Date:  1996-03-22       Impact factor: 1.837

4.  Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents.

Authors:  S S Chandrasekhar; R Y Rubinstein; J A Kwartler; M Gatz; P E Connelly; E Huang; S Baredes
Journal:  Otolaryngol Head Neck Surg       Date:  2000-04       Impact factor: 3.497

5.  In vivo delivery of recombinant viruses to the fetal murine cochlea: transduction characteristics and long-term effects on auditory function.

Authors:  Jeffrey C Bedrosian; Michael Anne Gratton; John V Brigande; Waixing Tang; Jessica Landau; Jean Bennett
Journal:  Mol Ther       Date:  2006-06-09       Impact factor: 11.454

6.  Sendai virus vector-mediated transgene expression in the cochlea in vivo.

Authors:  Sho Kanzaki; Akihiro Shiotani; Makoto Inoue; Mamoru Hasegawa; Kaoru Ogawa
Journal:  Audiol Neurootol       Date:  2006-12-06       Impact factor: 1.854

7.  Drug delivery to the cochlea using PLGA nanoparticles.

Authors:  Tetsuya Tamura; Tomoko Kita; Takayuki Nakagawa; Tsuyoshi Endo; Tae-Soo Kim; Tsutomu Ishihara; Yutaka Mizushima; Megumu Higaki; Juichi Ito
Journal:  Laryngoscope       Date:  2005-11       Impact factor: 3.325

8.  Delivery of neurotrophin-3 to the cochlea using alginate beads.

Authors:  Farnoosh Noushi; Rachael T Richardson; Jennifer Hardman; Graeme Clark; Stephen O'Leary
Journal:  Otol Neurotol       Date:  2005-05       Impact factor: 2.311

9.  Adeno-associated virus-mediated Bcl-xL prevents aminoglycoside-induced hearing loss in mice.

Authors:  Yu-He Liu; Xiao-Mei Ke; Yong Qin; Zhi-Ping Gu; Shui-Fang Xiao
Journal:  Chin Med J (Engl)       Date:  2007-07-20       Impact factor: 2.628

10.  Adenovirus-mediated expression of brain-derived neurotrophic factor protects spiral ganglion neurons from ototoxic damage.

Authors:  Toshihiko Nakaizumi; Kohei Kawamoto; Ryosei Minoda; Yehoash Raphael
Journal:  Audiol Neurootol       Date:  2004 May-Jun       Impact factor: 1.854

View more
  7 in total

Review 1.  [Gene therapy and stem cells for the inner ear: a review].

Authors:  H A Breinbauer; M Praetorius
Journal:  HNO       Date:  2014-02       Impact factor: 1.284

2.  Ultrasound-induced microbubble cavitation via a transcanal or transcranial approach facilitates inner ear drug delivery.

Authors:  Ai-Ho Liao; Chih-Hung Wang; Ping-Yu Weng; Yi-Chun Lin; Hao Wang; Hang-Kang Chen; Hao-Li Liu; Ho-Chiao Chuang; Cheng-Ping Shih
Journal:  JCI Insight       Date:  2020-02-13

Review 3.  New treatment options for hearing loss.

Authors:  Ulrich Müller; Peter G Barr-Gillespie
Journal:  Nat Rev Drug Discov       Date:  2015-03-20       Impact factor: 84.694

4.  A review of gene delivery and stem cell based therapies for regenerating inner ear hair cells.

Authors:  Keerthana Devarajan; Hinrich Staecker; Michael S Detamore
Journal:  J Funct Biomater       Date:  2011-09-13

5.  Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.

Authors:  Xue Gao; Yong Tao; Veronica Lamas; Mingqian Huang; Wei-Hsi Yeh; Bifeng Pan; Yu-Juan Hu; Johnny H Hu; David B Thompson; Yilai Shu; Yamin Li; Hongyang Wang; Shiming Yang; Qiaobing Xu; Daniel B Polley; M Charles Liberman; Wei-Jia Kong; Jeffrey R Holt; Zheng-Yi Chen; David R Liu
Journal:  Nature       Date:  2017-12-20       Impact factor: 49.962

Review 6.  Application of New Materials in Auditory Disease Treatment.

Authors:  Ming Li; Yurong Mu; Hua Cai; Han Wu; Yanyan Ding
Journal:  Front Cell Neurosci       Date:  2022-01-31       Impact factor: 5.505

7.  Expression Profile of New Gene Markers Involved in Differentiation of Canine Adipose-Derived Stem Cells into Chondrocytes.

Authors:  Maurycy Jankowski; Mariusz Kaczmarek; Grzegorz Wąsiatycz; Aneta Konwerska; Claudia Dompe; Dorota Bukowska; Paweł Antosik; Paul Mozdziak; Bartosz Kempisty
Journal:  Genes (Basel)       Date:  2022-09-16       Impact factor: 4.141

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.